Viatris, Inc. VTRS 深 沪
等待开盘 05-14 09:30:00 美东时间
17.37
+0.200
+1.16%
华盛通- 最 高17.39
- 今 开17.13
- 成交量 1431.72万股
- 最 低 16.96
- 昨 收 17.17
- 总市值 202.26亿
- 52周最高 17.53
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 7.96
- 委 比 39.35%
- 总股本 11.64亿
- 历史最高 17.53
- 量 比 0.69
- 振 幅 2.50%
- 历史最低 6.37
- 每 手 1
- 风险率 2.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Most healthcare companies report higher Y/Y EPS in strong earnings week
Healthcare companies delivered strong earnings this week, with 18 out of 20 companies beating EPS estimates and 15 topping revenue expectations, as resilient demand across pharmaceuticals, healthcare ...
05-09 23:30
HHS officials considered banning SSRI antidepressants - report
HHS officials recently discussed whether to ban selective serotonin reuptake inhibitors (SSRIs), among the most popular antidepressant medications prescribed, amid a push to reduce the use of the drug...
05-09 05:22
RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding
U.S. officials discussed possible SSRI restrictions as RFK Jr. unveiled a broader push to reduce antidepressant use.
05-09 02:22
Truist Securities Maintains Buy on Viatris, Raises Price Target to $20
Truist Securities analyst Srikripa Devarakonda maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $18 to $20.
05-09 01:31
财报速睇 | Viatris, Inc. 2026财年Q1营收35.17亿美元，同比增长8.1%；归母净利润1.76亿美元，扭亏为盈
华盛资讯5月8日讯，Viatris, Inc.公布2026财年Q1业绩，公司Q1营收35.17亿美元，同比增长8.1%，归母净利润1.76亿美元，扭亏为盈。
05-08 04:47
Viatris beats first-quarter estimates on China strength, branded drug sales
Viatris beats first-quarter estimates on China strength, branded drug sales May 7 (Reuters) - Viatris VTRS.O topped analysts' estimates for first-quarter revenue and profit on Thursday, buoyed by strength in its China business and strong demand for branded drugs. The company has been under pressure
05-07 20:58
Viatris Affirms FY2026 Adj EPS Guidance of $2.33-$2.47 vs $2.44 Est; Affirms FY2026 Sales Guidance of $14.450B-$14.950B vs $14.638B Est
Viatris (NASDAQ:VTRS) affirms FY2026 Adj EPS guidance from $2.33-$2.47 to $2.33-$2.47 vs $2.44 analyst estimate. Affirms FY2026 sales outlook from $14.450 billion-$14.950 billion to $14.450 billion-$14.950 billion vs
05-07 20:45
财报速睇 | Viatris, Inc. 2026财年Q1营收35.17亿美元，同比增长8.1%；归母净利润1.76亿美元，扭亏为盈
华盛资讯5月7日讯，Viatris, Inc.公布2026财年Q1业绩，公司Q1营收35.17亿美元，同比增长8.1%，归母净利润1.76亿美元，扭亏为盈。
05-07 20:12
Viatris Q1 FY26 returns to profit of $176 million; revenue rises 8% to $3.5 billion
Viatris Q1 FY26 returns to profit of $176 million; revenue rises 8% to $3.5 billion Viatris posted Q1 2026 net earnings of $176.4 million, swinging from a loss a year earlier, while revenue rose 8% to $3.52 billion. Adjusted EBITDA climbed 14% to $1.05 billion, with adjusted EPS up 18% to $0.59. Fre
05-07 18:59
